News Releases

20 May '22
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 20, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S.
20 May '22
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 20, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of
10 May '22
Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen Smith as CMO of combined company Planning corporate name change to Quince
15 Mar '22
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 15, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Marwan Noel
14 Mar '22
New data expands evidence base of role of P. gingivalis in Alzheimer’s disease Discussion to include new biomarker results   and correlations between biomarkers and clinical outcomes SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 14, 2022-- Cortexyme, Inc.
01 Feb '22
Next generation lysine gingipain inhibitor COR588 with novel structure and improved pharmacologic and safety profile prioritized for Alzheimer’s development Additional pipeline includes therapeutics in development for coronavirus infection, periodontal disease, and prevention of oral squamous cell
Displaying 11 - 20 of 22